Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 2Waldenstrom Macroglobulinemia 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Other Infectious Diseases 1Neoplasms, Plasma Cell 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Hairy Cell 1Leukemia 1Infections 1Hot Flashes 1Hodgkin Disease 1Hematologic Neoplasms 1Fever 1Febrile Neutropenia 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

ceftolozane 1Tazobactam 1Piperacillin, Tazobactam Drug Combination 1Meropenem 1Cefepime 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Other Infectious Diseases × Tazobactam × Clear all
NCT03485950 2022-03-15

Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam

M.D. Anderson Cancer Center

Phase 2 Completed
100 enrolled 33 charts

Other Infectious Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡